KTRAKintara Therapeutics, Inc.

Nasdaq kintara.com


$ 0.21 $ 0.00 (-0.58 %)    

Wednesday, 05-Jun-2024 12:02:00 EDT
QQQ $ 454.82 $ 3.59 (0.79 %)
DIA $ 398.57 $ -0.40 (-0.1 %)
SPY $ 530.36 $ 1.32 (0.25 %)
TLT $ 91.26 $ 0.26 (0.28 %)
GLD $ 225.37 $ 1.04 (0.48 %)
$ 0.223
$ 0.21
$ 0.15 x 1,000
$ 0.20 x 100
$ 0.19 - $ 0.21
$ 0.08 - $ 5.60
10,439,424
na
373,593
$ 0.80
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 11-13-2023 09-30-2023 10-Q
4 09-18-2023 06-30-2023 10-K
5 05-11-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-Q
7 11-09-2022 09-30-2022 10-Q
8 09-27-2022 06-30-2022 10-K
9 05-13-2022 03-31-2022 10-Q
10 02-11-2022 12-31-2021 10-Q
11 11-15-2021 09-30-2021 10-Q
12 09-28-2021 06-30-2021 10-K
13 05-13-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-Q
15 11-12-2020 09-30-2020 10-Q
16 09-18-2020 06-30-2020 10-K
17 05-13-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-Q
19 11-13-2019 09-30-2019 10-Q
20 09-09-2019 06-30-2019 10-K
21 05-14-2019 03-31-2019 10-Q
22 02-11-2019 12-31-2018 10-Q
23 11-13-2018 09-30-2018 10-Q
24 09-24-2018 06-30-2018 10-K
25 05-15-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-Q
27 11-09-2017 09-30-2017 10-Q
28 09-27-2017 06-30-2017 10-K
29 05-12-2017 03-31-2017 10-Q
30 02-10-2017 12-31-2016 10-Q
31 11-10-2016 09-30-2016 10-Q
32 09-13-2016 06-30-2016 10-K
33 05-12-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-Q
35 11-16-2015 09-30-2015 10-Q
36 09-03-2015 06-30-2015 10-K
37 05-15-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-Q
39 11-07-2014 09-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tuhura-biosciences-and-kintara-therapeutics-announce-phase-1b-trial-of-ifx-20-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-results

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI ...

 watching-kintara-therapeutics-traders-circulate-a-congressional-trade-report-over-the-weekend-disclosed-that-florida-congresswoman-laurel-lee-made-a-100k-250k-convertible-promissory-note-investment-in-kintara-therapeutics-merger-company-tuhura-biosciences

https://disclosures-clerk.house.gov/public_disc/ptr-pdfs/2024/20025116.pdf

 kintara-therapeutics-q3-2024-gaap-eps-005

Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(0.05) per share.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION